Updated data from CheckMate 9LA in advanced NSCLC show continuing benefit
Updated data from the CheckMate 9LA study shows that nivolumab plus ipilimumab with to cycles of chemotherapy gave a significant improvement of overall survival compared to chemotherapy alone in patients with non-small cell lung cancer (NSCLC). Data supports treatment with combinations in first line advanced NSCLC.
Get access to the article
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.